Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Pregnancy (7)
- Animals (2)
- Female (2)
- Humans (2)
- Placenta (2)
-
- Pre-eclampsia (2)
- Adenosine Diphosphate (1)
- Antepartum testing (1)
- Anti-Mullerian hormone (1)
- Anti-Müllerian hormones (1)
- Antihypertensive Agents (1)
- Benzylamines (1)
- DNA (1)
- Delivery (1)
- Drug Administration Routes (1)
- Drug Design (1)
- Drug Evaluation (1)
- Drug Evaluation, Preclinical (1)
- Endothelium (1)
- Endothelium, Vascular (1)
- Exosome (1)
- Fetal Diseases (1)
- Fetal sex (1)
- Genetic Predisposition to Disease (1)
- Genome (1)
- Genome, Human (1)
- Hematopoiesis (1)
- Human (1)
- Immune System (1)
- Labor (1)
- File Type
Articles 1 - 11 of 11
Full-Text Articles in Entire DC Network
Indoleamine 2,3 Dioxygenase (Ido) Deficiency Results: In Vascular Dysfunction And Proteinuria In Pregnancy, Mark Santillan, Christopher Pelham, Pimonrat Ketsawatsomkron, Donna Santillan, Baoli Yang, Stephen Hunter, Curt Sigmund
Indoleamine 2,3 Dioxygenase (Ido) Deficiency Results: In Vascular Dysfunction And Proteinuria In Pregnancy, Mark Santillan, Christopher Pelham, Pimonrat Ketsawatsomkron, Donna Santillan, Baoli Yang, Stephen Hunter, Curt Sigmund
Mark K. Santillan
No abstract provided.
Preeclampsia And Micrornas, Eric J. Devor, Donna A. Santillan, Mark K. Santillan
Preeclampsia And Micrornas, Eric J. Devor, Donna A. Santillan, Mark K. Santillan
Mark K. Santillan
Preeclampsia is a critical gestational condition that threatens the life of both mother and child. One of the most serious aspects of preeclampsia hampering both clinical management and scientific understanding is that there are, as yet, no early warning signs or risk markers. The discovery of microRNAs (miRNAs), tiny post-transcriptional regulators of gene expression, offers potentially fertile ground for developing such markers. The current state of knowledge about miRNAs in preeclampsia is presented along with information regarding miRNA detection in peripheral fluids that could lead to minimally invasive risk assessment.
University Of Iowa Dept. Of Obstetrics And Gynecology Partners With Preeclampsia Foundation, Mark K. Santillan
University Of Iowa Dept. Of Obstetrics And Gynecology Partners With Preeclampsia Foundation, Mark K. Santillan
Mark K. Santillan
The Preeclampsia Foundation is the only national 501(c)(3) not-for-profit patient advocacy organization serving the 5-8% of pregnant women - 300,000 women each year in the U.S. - who are affected by hypertensive disorders of pregnancy such as preeclampsia (formerly known as toxemia), eclampsia and HELLP syndrome. Their mission is to reduce maternal and infant illness and death due to preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy by providing patient support and education, raising public awareness, catalyzing research and improving healthcare practices.
The Preeclampsia Foundation and the Department of Obstetrics and Gynecology of the University of Iowa will be …
The Effects Of Preeclampsia On Signaling To Hematopoietic Progenitor Cells, Donna A. Santillan, Wendy S. Hamilton, Ashley Christensen, Katelyn M. Talcott, Lindsay K. Gravatt, Mark K. Santillan, Stephen K. Hunter
The Effects Of Preeclampsia On Signaling To Hematopoietic Progenitor Cells, Donna A. Santillan, Wendy S. Hamilton, Ashley Christensen, Katelyn M. Talcott, Lindsay K. Gravatt, Mark K. Santillan, Stephen K. Hunter
Mark K. Santillan
Background: The role of the microenvironment is important in cell differentiation. The effect of placental disease on the growth and differentiation and hematopoietic stem cells has not been well-studied.
Methods: Enzyme linked immunoassay was used to measure erythropoietin and osteopontin in plasma from umbilical cord blood of children born to normotensive and preeclamptic women. Additionally, CD34+ cells were isolated from umbilical cord blood and grown in complete methylcellulose media. Colony types were identified and enumerated.
Results: Differences in the concentration of erythropoietin in the cord blood between the controls and the preeclamptics approached significance (P = 0.067) using a Mann-Whitney …
Fetal Effects Of Drugs Commonly Used In Critical Care, Mark Santillan, J. Yankowitx
Fetal Effects Of Drugs Commonly Used In Critical Care, Mark Santillan, J. Yankowitx
Mark K. Santillan
No abstract provided.
"Caught Between A Rock And A Hard Place: Obesity And Delivery Decisions", Mark Santillan
"Caught Between A Rock And A Hard Place: Obesity And Delivery Decisions", Mark Santillan
Mark K. Santillan
The incidence of obesity has achieved epidemic proportions. The increase in the proportion of women gaining more than 40 pounds during pregnancy and the related increased perinatal morbidity demonstrates how obesity has affected the reproductive outcomes for women. Individualized counseling and preparation for the needs of an obese woman in labor are at the cornerstone of managing obese women in labor and delivery.
The Effect Of A Novel Glycoprotein Iib/Iiia Antagonist, Sr 121566a, On Platelet Aggregation And Activation In Rhesus Monkeys., Mark Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J. Herbert, J. Fareed
The Effect Of A Novel Glycoprotein Iib/Iiia Antagonist, Sr 121566a, On Platelet Aggregation And Activation In Rhesus Monkeys., Mark Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J. Herbert, J. Fareed
Mark K. Santillan
SR 121566A represents a peptidomimetic glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor 3-[N- 4-[4-(aminoiminomethyl)phenyl]-1,3-thiazol-2-yl ) -N-(1-carboxymethylpiperid-4-yl) amino] propionic acid, trihydrochloride. To investigate the intravenous and subcutaneous pharmacodynamics of this agent, a primate model ( Macaca mulatta) was used. The IC50 for adenosine diphosphate (ADP) (10 micromol/L)-induced platelet aggregation in this primate platelet system was found to be 45 +/- 6 nmol/L. Comparatively in the human platelet rich plasma system, SR 121566A demonstrated an IC50 of 39 +/- 4 nmol/L. Graded doses of SR 121566A in the range of 25-400 microg/kg were administered intravenously. Blood samples were drawn from individual groups of primates …
The Influence Of Fetal Sex On Patterns Of Change In Anti-Mullerian Hormone During Pregnancy, Ryan Empey, Donna Santillan, Mark Santillan, Eric Tyler, Stephen Hunter, Elaine Smith, Barbara Stegmann
The Influence Of Fetal Sex On Patterns Of Change In Anti-Mullerian Hormone During Pregnancy, Ryan Empey, Donna Santillan, Mark Santillan, Eric Tyler, Stephen Hunter, Elaine Smith, Barbara Stegmann
Mark K. Santillan
Maternal anti-mullerian hormone declines sharply between 13-15 weeks, likely as a result of feto-placental signaling. Fetal AMH levels are known to be widely disparate after the first trimester, with high levels in male and absent levels in female. However, it is unclear as to whether differing fetal AMH levels influence the pattern of change of maternal AMH. Our objective was to examine AMH throughout gestation to determine if the maternal concentration varies according to the gender of the fetus.
From Molecules To Medicine: A Future Cure For Preeclampsia?, Mark Santillan, Donna Santillan, Curt Sigmund, Stephen Hunter
From Molecules To Medicine: A Future Cure For Preeclampsia?, Mark Santillan, Donna Santillan, Curt Sigmund, Stephen Hunter
Mark K. Santillan
In the United States, preeclampsia (PreE) affects 5-7% of all pregnancies, yet represents 15% of all maternal-fetal morbidity and mortality. PreE causes fetal growth restriction, oligohydramnios, fetal death, and maternal seizures, stroke, cerebrovascular hemorrhage and death. It has immediate and potentially long-term effects on both the fetus and mother. To date, the molecular pathogenesis of PreE is largely unknown. Multiple pathways, including dysfunctional angiogenesis, inappropriate placentation, oxidative stress and an altered immunological milieu have been proposed as key players in the development of PreE. In addition, genetic factors in all of these pathways are essential components in the etiology of …
Non-Invasive Fetal Genome Sequencing: Opportunities And Challenges., Holly Tabor, Jeffrey Murray, Hilary Gammill, Jacob Kitzman, Matthew Snyder, Mario Ventura, Alexandra Lewis, Ruolan Qiu, Lavone Simmons, Craig Rubens, Mark Santillan, Evan Eichler, Edith Cheng, Michael Bamshad, Jay Shendure
Non-Invasive Fetal Genome Sequencing: Opportunities And Challenges., Holly Tabor, Jeffrey Murray, Hilary Gammill, Jacob Kitzman, Matthew Snyder, Mario Ventura, Alexandra Lewis, Ruolan Qiu, Lavone Simmons, Craig Rubens, Mark Santillan, Evan Eichler, Edith Cheng, Michael Bamshad, Jay Shendure
Mark K. Santillan
No abstract provided.
Anti-Müllerian Hormone Concentration Levels In Maternal Plasma During The First, Second And Third Trimester Of Pregnancy, Kelin Schultz, Barbara Stegmann, Mark Santillan, Donna Santillan, Elaine Smith, Bradley J. Van Voorhis
Anti-Müllerian Hormone Concentration Levels In Maternal Plasma During The First, Second And Third Trimester Of Pregnancy, Kelin Schultz, Barbara Stegmann, Mark Santillan, Donna Santillan, Elaine Smith, Bradley J. Van Voorhis
Mark K. Santillan
Follicle-Stimulating Hormone (FSH) drops rapidly in pregnancy but Anti-Mullerian Hormone (AMH) has not been shown to drop until about 12 weeks. Since the follicles that secrete AMH are thought to be FSH independent, AMH levels should slowly decline in the absence of FSH because when the follicles reach FSH dependence, they would die off. A study has presented data that suggests a decline in AMH levels suddenly starts at 12 weeks gestation. The present study agrees with a decline in AMH after the first trimester. There is a sharp decline in AMH at 12-16 weeks gestation indicating that the follicular …